Trials / Withdrawn
WithdrawnNCT05156645
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
An Adaptive Phase I/II/III Trial to Evaluate the Efficacy and Safety of Anti-SARS-CoV-2 Monoclonal Antibody Combination (SCTA01C and SCTA01) for Treatment of Outpatients With COVID-19
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sinocelltech Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of Care (SOC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCTA01 and SCTA01C | Diluted by 0.9% normal saline |
| DRUG | Placebo | Diluted by 0.9% normal saline |
Timeline
- Start date
- 2022-01-15
- Primary completion
- 2022-12-01
- Completion
- 2022-12-01
- First posted
- 2021-12-14
- Last updated
- 2022-01-27
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05156645. Inclusion in this directory is not an endorsement.